bevacizumab-vikg
| Brand name | Lytenava |
|---|---|
| Active ingredient | bevacizumab-vikg |
| Strength | 1.25MG (0.05ML of 25MG/ML) |
| Dosage form | Injection |
| Route | Intravitreal |
| Modality | Biologic |
| FDA approval | July 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.